NSCLC, metastatic 2
Invited discussant LBA45, LBA47_PR and abstract 1202O
Date
10 Oct 2016Session
NSCLC, metastatic 2Presenters
Tony S.K. MokAuthors
T.S.K. MokAuthor affiliations
- Clinical Oncology, The Chinese University of Hong Kong, NA - Hong Kong/CN
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
4589 - Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
Presenter: David Spigel
Session: NSCLC, metastatic 2
Resources:
Abstract
Slides
2411 - Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
Presenter: Pasi Jänne
Session: NSCLC, metastatic 2
Resources:
Abstract
Slides
2311 - Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Presenter: Charlotte Leduc
Session: NSCLC, metastatic 2
Resources:
Abstract